How to Get Repatha (Evolocumab) in Maryland

What Is Repatha and Why Maryland Patients Need It

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab restores receptor recycling and reduces LDL-cholesterol by 50 to 60 percent on top of maximally tolerated statin therapy. The FDA granted full approval for three indications: heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering [1].

Maryland has roughly 1 in 250 residents carrying a pathogenic variant associated with HeFH, consistent with the global prevalence reported by the American Heart Association [2]. Many of those patients remain on statins alone despite LDL levels above guideline targets. The 2018 ACC/AHA Cholesterol Guideline recommends considering a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients on maximally tolerated statin plus ezetimibe [3]. Repatha gives Maryland clinicians a validated tool to close that gap.

The FOURIER trial (N=27,564) established the cardiovascular outcome benefit that underlies Maryland Medicaid and commercial payer coverage criteria. Patients receiving evolocumab 140 mg every two weeks achieved a mean LDL-C reduction of 59% from baseline (from 92 mg/dL to 30 mg/dL) and experienced a 15% relative risk reduction in the primary composite endpoint of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina (HR 0.85 to 95% CI 0.79-0.92, P<0.001) at a median follow-up of 2.2 years [4].

The GLAGOV trial (N=968) added imaging evidence: evolocumab produced significant regression of coronary atherosclerosis (percent atheroma volume reduced by 0.95% vs. increase of 0.05% on placebo, P<0.001) over 78 weeks [5].

Who Can Prescribe Repatha in Maryland

Any Maryland-licensed prescriber with DEA authority can write for Repatha. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) working within their scope of practice. Maryland law grants NPs full practice authority under the Maryland Nurse Practice Act, meaning they can prescribe independently without a required physician collaborator agreement for most ambulatory settings [6]. PAs in Maryland may prescribe under a delegation agreement with a supervising physician.

In practice, most Repatha prescriptions originate from cardiologists, lipidologists, and internal medicine physicians, because prior authorization requirements often demand documentation of specialist-level workup. A 2023 analysis in the Journal of the American College of Cardiology found that PCSK9 inhibitor prescribing rates are significantly lower in primary care compared to cardiology settings, largely due to PA burden rather than clinical appropriateness [7].

Telehealth prescribing is fully permitted in Maryland for evolocumab when a valid patient-provider relationship has been established. Maryland follows federal telehealth rules that allow prescription of non-controlled medications via synchronous audio-video visits [8]. A prescriber licensed in Maryland does not need a separate telehealth-specific license; their standard Maryland license covers remote prescribing.

Step-by-Step: How to Get a Repatha Prescription in Maryland

Getting from "I need Repatha" to first injection involves four discrete stages.

Stage 1: Establish eligibility. Repatha is FDA-approved and guideline-recommended for HeFH, HoFH, and very-high-risk ASCVD. For ASCVD, the 2022 ACC Expert Consensus Decision Pathway defines "very high risk" as two or more major ASCVD events, or one major event plus multiple high-risk conditions [9]. For FH, a Simon Broome or Dutch Lipid Clinic Network score should be documented, as many Maryland payers require it during PA.

Stage 2: Obtain baseline labs. Order a fasting lipid panel and hepatic function panel before the first prescription. Some payers also require documentation of a prior trial on high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) and, where tolerated, ezetimibe 10 mg. Lab results generally need to be dated within 90 days of the PA submission.

Stage 3: Submit prior authorization. Your prescriber or their office submits the PA to your insurer. Required documentation typically includes: current LDL-C value, evidence of maximally tolerated statin use (or documented statin intolerance with a CK level and clinical note), diagnosis code (E78.01 for HeFH, E78.02 for HoFH, or relevant ICD-10 for ASCVD), and prescriber NPI. Maryland Medicaid (Maryland Medical Assistance) covers evolocumab with PA under these criteria, consistent with CMS guidance on PCSK9 inhibitors for FH and ASCVD [10].

Stage 4: Specialty pharmacy fulfillment. Once PA is approved, the prescription routes to a specialty pharmacy. Amgen's dedicated specialty pharmacy network includes Accredo, CVS Specialty, and Walgreens Specialty. First fill typically ships within five to seven business days of PA approval. The SureClick autoinjector (140 mg/mL prefilled) or the Pushtronex monthly system (420 mg/3.5 mL) arrives cold-packed. Patients should have a sharps container ready.

Maryland Telehealth Providers Prescribing Repatha

Maryland adopted permanent telehealth flexibilities post-pandemic. Synchronous audio-video visits satisfy the clinical evaluation requirement for Repatha prescribing. Platforms operating in Maryland must comply with the Maryland Telemedicine Act, which prohibits prescribing solely on the basis of an online questionnaire without a real-time evaluation [11].

HealthRX connects Maryland patients to board-certified clinicians for lipid management via telehealth. A typical telehealth flow for Repatha in Maryland works as follows: the patient completes an intake form and uploads recent lab results, the clinician conducts a synchronous video visit (average 20-30 minutes for a new lipid consult), the prescriber determines eligibility and submits PA, and the specialty pharmacy ships directly to the patient's Maryland address. No in-person visit is required at any step after labs are drawn at a local lab.

The ACC/AHA 2022 Expert Consensus notes that "clinicians should consider patient access barriers, including geographic distance from specialty care, when selecting cholesterol-lowering therapy" [9]. Telehealth directly addresses that barrier for Maryland residents outside the Baltimore-Washington corridor.

Prior Authorization Requirements in Maryland: Payer-by-Payer Overview

PA requirements vary by payer, but all Maryland commercial plans operating under ACA marketplace rules must follow evidence-based medical necessity standards. Here is what the three largest Maryland payer categories typically require.

CareFirst BlueCross BlueShield Maryland: Requires documented LDL-C at or above 70 mg/dL on maximally tolerated statin for ASCVD, or LDL-C at or above 100 mg/dL for HeFH. Minimum 90-day trial of high-intensity statin unless statin intolerance is documented with a creatine kinase level exceeding three times the upper limit of normal on two separate occasions [12].

Maryland Medicaid (Medical Assistance): Covers evolocumab for HeFH (Simon Broome criteria or genetic confirmation) and established ASCVD with LDL-C above 70 mg/dL despite statin and ezetimibe. PA duration is typically 12 months before re-authorization. The Centers for Medicare and Medicaid Services published guidance reinforcing PCSK9 inhibitor coverage for FH as medically necessary when criteria are met [10].

Medicare Part D (for Maryland residents 65+): Subject to formulary tier placement by individual plan. The 2024 IRA drug negotiation process has affected some specialty drug pricing, but evolocumab remains available under Part D with PA. Maryland SHIP (State Health Insurance Assistance Program) counselors can help beneficiaries compare plans [13].

Appeal rights matter. If PA is denied, Maryland law requires insurers to provide a written denial with clinical rationale, and patients have the right to an expedited external appeal within 72 hours for urgent conditions [14]. The Maryland Insurance Administration oversees this process.

What Labs Are Needed Before Starting Repatha in Maryland

Clinicians need three data points before writing the first Repatha prescription.

A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C) forms the core of eligibility determination and is required by virtually every payer PA form. The Friedewald equation used to calculate LDL-C becomes unreliable when triglycerides exceed 400 mg/dL; in that scenario, a direct LDL-C measurement or Martin-Hopkins equation should be used [15].

A hepatic function panel (ALT, AST, bilirubin, alkaline phosphatase) establishes baseline liver status. Evolocumab is not hepatotoxic at approved doses, but baseline documentation protects against attribution of incidental liver findings to the drug later [1].

A creatine kinase (CK) level, while not universally required, is valuable when the PA form requests documentation of statin intolerance. CK above 10 times the upper limit of normal on a statin constitutes severe myopathy and provides unambiguous grounds for statin intolerance [16].

Labs should be dated within 90 days of PA submission; most payers reject results older than 180 days outright. A Quest Diagnostics or LabCorp draw site serves virtually every Maryland ZIP code, and results can be shared electronically with a telehealth prescriber via the patient portal.

Repatha Dosing, Administration, and Storage

Two dosing regimens carry FDA approval and produce equivalent LDL reduction at steady state [1].

The 140 mg every-two-weeks regimen uses the SureClick autoinjector or the prefilled syringe. Injection sites are the abdomen, thigh, or upper arm. Rotating sites reduces injection-site reactions, which occurred in 2.4% of FOURIER participants [4].

The 420 mg once-monthly regimen uses either three consecutive 140 mg injections within 30 minutes or the Pushtronex on-body infusor system. The on-body system delivers the full 420 mg over nine minutes and is preferred by patients who find three separate injections inconvenient.

Storage: refrigerate at 36 to 46 degrees Fahrenheit. Repatha may be stored at room temperature (up to 77 degrees Fahrenheit) for a single period of up to 30 days. Do not freeze. Do not shake. The prefilled device should reach room temperature for 30 minutes before injection to reduce injection-site discomfort [1].

Monitoring after initiation: recheck fasting lipid panel four to twelve weeks after starting therapy to confirm LDL-C response and satisfy any payer re-authorization requirement. The ACC/AHA 2018 guideline recommends a treatment goal of at least 50% LDL-C reduction in very-high-risk patients, with an optional numeric goal of LDL-C below 70 mg/dL [3].

Repatha Cost and Financial Assistance in Maryland

List price for Repatha is approximately $700 per month without insurance. That figure rarely reflects what patients actually pay, because multiple assistance programs apply.

Amgen's Repatha SupportPlus program offers a copay card that reduces out-of-pocket cost to as low as $5 per month for commercially insured patients who meet income criteria [17]. Eligibility and enrollment are handled online at Amgen's patient-support portal.

Patients without commercial coverage may qualify for the Amgen Safety Net Foundation, which provides Repatha at no cost to patients with household income at or below 500% of the federal poverty level who lack adequate prescription coverage [17].

Maryland's Prescription Drug Affordability Board (PDAB), established under HB 19 (2019), reviews high-cost drugs and can set upper payment limits for state-covered populations. As of 2025, evolocumab has been reviewed by PDAB as part of the board's ongoing specialty drug affordability assessments; Maryland residents should check the PDAB website for the most current status [18].

Can a 503A Pharmacy in Maryland Compound Evolocumab?

503A pharmacies compound medications for individual patients under a valid prescription from a licensed prescriber. Maryland-licensed 503A pharmacies are regulated by the Maryland Board of Pharmacy and must comply with USP 797 sterile compounding standards [19].

Evolocumab, however, is a full-length human monoclonal antibody produced through recombinant DNA technology in Chinese hamster ovary cells. That manufacturing process is not reproducible in a 503A compounding pharmacy setting. The FDA's stance is that biologics like evolocumab are not suitable candidates for traditional compounding [20]. There is no compounded evolocumab available in Maryland or any other state. Patients need branded Repatha from Amgen's specialty pharmacy network.

This is a meaningful distinction from small-molecule drugs (like semaglutide during shortage periods), where 503A compounding has been used. For PCSK9 inhibitors, branded product is the only legal and clinically validated option.

Transferring an Existing Repatha Prescription to Maryland

Patients relocating to Maryland with an active Repatha prescription from another state have two practical paths.

First, the existing specialty pharmacy can continue shipping to a Maryland address as long as the pharmacy holds Maryland pharmacy licensure and the prescriber holds a valid license in Maryland (or the patient establishes care with a Maryland-licensed prescriber). Specialty pharmacy networks like Accredo and CVS Specialty hold licenses in all 50 states and can update a shipping address without requiring a new prescription in most cases.

Second, the patient can transfer care to a Maryland-licensed prescriber, who writes a new prescription and submits a new PA to the patient's insurer. Maryland law does not require patients to use a Maryland-based prescriber for a non-controlled substance, but most payers require the prescribing provider to hold an active license in the patient's state of residence for PA approval.

The Maryland Board of Pharmacy confirms that out-of-state pharmacies may ship non-controlled prescription drugs to Maryland residents as long as the shipping pharmacy is licensed in Maryland [19].

Safety Profile and Contraindications

Evolocumab's adverse event profile in FOURIER (N=27,564, median 2.2 years) was comparable to placebo for serious adverse events [4]. The most common adverse reactions in the FDA label are: nasopharyngitis (12.7%), upper respiratory tract infection (9.3%), influenza (7.5%), back pain (5.6%), and injection-site reactions (2.4%) [1].

Neurocognitive effects were evaluated in the EBBINGHAUS substudy (N=1,204). Investigators found no significant difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery at 19 months of follow-up (P=0.72) [21]. This directly addresses the concern raised during early PCSK9 inhibitor development about very low LDL-C and cognitive function.

Evolocumab is contraindicated in patients with a known hypersensitivity to any component of the product. Hypersensitivity reactions, including rash, urticaria, and angioedema, have been reported [1]. Pregnancy and lactation data are limited; the 2018 ACC/AHA guideline notes that statins and PCSK9 inhibitors should generally be discontinued during pregnancy [3].

New-onset diabetes was not significantly increased with evolocumab in FOURIER (HR 1.05 to 95% CI 0.94-1.17), a meaningful contrast to the modest diabetes signal observed with intensive statin therapy [4, 22].

Monitoring Timeline After Starting Repatha in Maryland

Week 0: Baseline fasting lipid panel, LFTs, and CK (if statin intolerance documented). Prescriber submits PA.

Week 1-2: Specialty pharmacy ships first supply after PA approval. Patient completes training on autoinjector or Pushtronex device.

Week 4-8: First injection-site check (telehealth visit acceptable). Most patients achieve maximum LDL-C reduction within four weeks of the first dose [1].

Week 12: Recheck fasting lipid panel. Confirm at least 50% LDL-C reduction. Submit results to payer for re-authorization if required.

Month 12: Annual PA re-authorization for most Maryland payers. Prescriber reconfirms diagnosis, current LDL-C, and absence of safety signals. The ACC/AHA guideline recommends reassessing absolute ASCVD risk every three to five years in stable patients, but Repatha re-authorization requires annual documentation [3].

A 12-month LDL-C monitoring cadence aligns with what the National Lipid Association recommends for patients on PCSK9 inhibitor therapy [23].